CD274 and cancer: Atezolizumab, durvalumab, and avelumab are three FDA-licensed PDL-1 inhibitors for more than ten cancer types, including melanoma, NSCLC, head and neck squamous cell carcinoma, esophageal cancer, gastric cancer, kidney cancer, bladder cancer, cervical cancer, Hodgkin’s and non-Hodgkin’s lymphoma, Merkel cell carcinoma, and colorectal cancer.